[
    [
        {
            "time": "",
            "original_text": "贝达药业(300558.SZ)收到埃克替尼术后辅助治疗临床试验数据核查通知",
            "features": {
                "keywords": [
                    "贝达药业",
                    "埃克替尼",
                    "术后辅助治疗",
                    "临床试验",
                    "数据核查"
                ],
                "sentiment_score": -0.2,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)收到埃克替尼术后辅助治疗临床试验数据核查通知",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "贝达药业(300558.SZ)：贝成投资减持期届满 累计减持436.05万股 减持股份",
            "features": {
                "keywords": [
                    "贝达药业",
                    "贝成投资",
                    "减持",
                    "436.05万股"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：贝成投资减持期届满 累计减持436.05万股 减持股份",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "贝达药业：贝成投资合计减持1.09%公司股份 减持股份",
            "features": {
                "keywords": [
                    "贝达药业",
                    "贝成投资",
                    "减持",
                    "1.09%"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业：贝成投资合计减持1.09%公司股份 减持股份",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "67个新药获批临床：恒瑞、先声、石四药",
            "features": {
                "keywords": [
                    "新药",
                    "获批临床",
                    "恒瑞",
                    "先声",
                    "石四药"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "67个新药获批临床：恒瑞、先声、石四药",
                "Correlation": 5,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业报告：把握业绩好 确定性较强的子行业",
            "features": {
                "keywords": [
                    "医药生物",
                    "行业报告",
                    "业绩",
                    "确定性",
                    "子行业"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业报告：把握业绩好 确定性较强的子行业",
                "Correlation": 4,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药行业周报：医药板块延续调整 关注优秀细分领域龙头机会",
            "features": {
                "keywords": [
                    "医药行业",
                    "周报",
                    "医药板块",
                    "调整",
                    "细分领域",
                    "龙头"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药行业周报：医药板块延续调整 关注优秀细分领域龙头机会",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 2,
                "Market_Scope": 10,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "恒瑞、先声、石四药……67个新药获批临床！豪森拿下首个口溶膜制剂，默沙东新药来了",
            "features": {
                "keywords": [
                    "恒瑞",
                    "先声",
                    "石四药",
                    "新药",
                    "获批临床",
                    "豪森",
                    "口溶膜制剂",
                    "默沙东"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "恒瑞、先声、石四药……67个新药获批临床！豪森拿下首个口溶膜制剂，默沙东新药来了",
                "Correlation": 5,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]